RESUMO
Objective To investigate the effects of rosiglitazone (RSG) on the levels of serum HbA1c, interleukin-6(IL-6) and high sensitive C-reactive protein (hsCRP) in type 2 diabetic patients who were inadequately controlled only with insulin therapy. Methods 40 patients with type 2 diabetes mellitus (T2DM), whose blood glucose was poorly controlled (HbA1c≥7 5%) after 4 weeks of standardized insulin therapy, were additionally given 4mg daily PSG. The levels of serum HbA1c, IL-6, hsCRP, total cholesterol (Tch), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) were measured before and after 12 weeks treatment with RSG. hsCRP was measured by high-sensitivity immunoturbidimetric method, and IL-6 by enzyme-linked immunoadsorbent assay (ELISA). Results ⑴ RSG 4mg daily significantly improved glycemic control, treatment with RSG 4 mg plus insulin resulted in a mean 1 59% reduction of HbA1c from baseline (P